📰 Multicenter Study News
Multicenter Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multicenter Study. Real-time updates on events, politics, business and more.
December 10, 2023
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –
December 10, 2023
Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.
November 30, 2023
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain...
November 30, 2023
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in
November 7, 2023
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics hereafter) announced that two major clinical updates...
November 6, 2023
MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles Company announcement, Inside Information TURKU, Finland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmac...
November 3, 2023
– Three Oral Presentations and 30 Posters Across HBV, HCV, HDV, and Fibrosis, Including Late-Breaking Data on Hepcludex® in HDV, Demonstrate Gilead’s Commitment to Addressing Unmet Needs for...
November 2, 2023
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support
October 13, 2023
Sickle cell disease, a chronic debilitating disorder, is characterized by ongoing hemolytic anemia, vaso-occlusive events, and progressive organ damage.
October 3, 2023
– First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitaes product and lab quality – – Sets...